Shares of Poseida Therapeutics, Inc. (PSTX) are trading -9% lower at a price of $3.74 at the time of this writing.

Poseida Therapeutics, Inc. has been trading between a 52-week high of $11.1 and a 52-week low of $1.82. The stock has a market cap of $235 Million.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable Poseida Therapeutics to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

Poseida Therapeutics stock slides on pricing $70M stock offering
Seeking Alpha 08-04-22

Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
PR Newswire 08-04-22

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Benzinga 08-04-22

Poseida Therapeutics stock slides on proposed stock offering (NASDAQ:PSTX)
Seeking Alpha 08-03-22

Poseida Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire 08-03-22